News | April 24, 2025
Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The 27 greenfield labs across the country ensure timely and accurate reporting
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
This unit will focus on the manufacturing of health and wellness equipment
Subscribe To Our Newsletter & Stay Updated
